Profile data is unavailable for this security.
About the company
Indoco Remedies Limited is an India-based fully integrated, research-oriented pharmaceutical company. The Company is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The Company caters to both Domestic and International markets. Its products include SENSODENT-K, HOMIDE, DEXOREN-S, LORCHEK-MR, SENSOFORM, KIDODENT, NINAF, KARVOL PLUS, CYCLOPAM, LIGNOX+ADRENLINE, NOXA, CITAL-UTI, RENOLEN, REXIDIN-M, CITAL, SENSODENT-KF, CARMICIDE, TOBAREN-DM, FEBREX PLUS, SCABEX, CLOBEN-G, MOFLOREN-BF, OTOREX, ZINCOREN, SENOLIN, LIGNOX, HEMSYL, FEDRIS, REXIDIN, VEPAN, OXIPOD, TURBOCORT, MACUCHEK, and DENTOGEL. The Company has around 11 manufacturing facilities, seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs), supported by a research and development center and a clinical research organization facility.
- Revenue in INR (TTM)17.58bn
- Net income in INR-1.14bn
- Incorporated1947
- Employees6.05k
- LocationIndoco Remedies Ltd166 Indoco HouseCst Road, Santacruz EastMUMBAI 400098IndiaIND
- Phone+91 2 226541851
- Fax+91 2 226523067
- Websitehttps://www.indoco.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lincoln Pharmaceuticals Ltd | 6.52bn | 878.34m | 12.40bn | 1.85k | 14.11 | -- | 12.17 | 1.90 | 43.86 | 43.86 | 325.55 | -- | -- | -- | -- | 3,518,272.00 | -- | 13.22 | -- | 15.46 | 53.64 | 50.82 | 13.47 | 14.56 | -- | 77.35 | -- | 3.32 | 7.35 | 10.03 | -11.74 | 9.87 | 20.13 | -- |
| Hester Biosciences Ltd | 3.14bn | 409.47m | 13.12bn | 562.00 | 40.93 | -- | 22.01 | 4.17 | 37.69 | 37.69 | 277.25 | -- | -- | -- | -- | 5,594,555.00 | -- | 5.39 | -- | 6.72 | 73.52 | 64.87 | 13.51 | 11.44 | -- | 9.65 | -- | 23.77 | 2.15 | 11.16 | 45.52 | -1.18 | -22.47 | 1.18 |
| Ngl Fine Chem Ltd | 4.47bn | 353.73m | 14.84bn | 456.00 | 41.95 | -- | 27.88 | 3.32 | 57.26 | 57.26 | 723.35 | -- | -- | -- | -- | 9,799,871.00 | -- | 13.34 | -- | 17.44 | 51.62 | 41.63 | 7.92 | 12.15 | -- | 9.06 | -- | 2.85 | 8.73 | 19.41 | -48.87 | 20.44 | 53.91 | 0.00 |
| Windlas Biotech Ltd | 8.68bn | 667.47m | 15.84bn | 1.35k | 23.89 | -- | 16.19 | 1.82 | 31.46 | 31.46 | 409.16 | -- | -- | -- | -- | 6,450,929.00 | -- | 8.65 | -- | 11.81 | 38.34 | 34.09 | 7.69 | 7.70 | -- | 15.80 | -- | 18.33 | 20.43 | 18.24 | 4.82 | 30.34 | 27.99 | -- |
| Amrutanjan Health Care Ltd | 4.88bn | 569.03m | 16.79bn | 631.00 | 29.52 | -- | 26.56 | 3.44 | 19.68 | 19.68 | 168.85 | -- | -- | -- | -- | 7,736,897.00 | -- | 15.84 | -- | 19.67 | 50.87 | 52.17 | 11.66 | 13.26 | -- | 319.69 | -- | 19.82 | 7.26 | 11.56 | 13.03 | 15.17 | 69.46 | 26.76 |
| Indoco Remedies Ltd | 17.58bn | -1.14bn | 18.51bn | 6.05k | -- | -- | 289.73 | 1.05 | -12.52 | -12.52 | 197.86 | -- | -- | -- | -- | 2,905,519.00 | -- | 4.84 | -- | 6.87 | 71.18 | 65.70 | -6.62 | 5.16 | -- | -0.3334 | -- | 17.11 | -8.38 | 8.51 | -174.89 | -- | 43.53 | -7.79 |
| Panacea Biotec Ltd | 6.06bn | -77.80m | 19.99bn | 1.29k | -- | -- | 79.47 | 3.30 | -1.27 | -1.27 | 98.66 | -- | -- | -- | -- | 4,694,217.00 | -- | 13.08 | -- | 19.61 | 57.70 | 48.06 | -1.35 | 30.99 | -- | -11.50 | -- | 0.00 | -0.0132 | 0.5466 | -613.56 | -- | 48.74 | -- |
| Solara Active Pharma Sciences Ltd | 12.55bn | -191.10m | 20.33bn | 1.78k | -- | -- | 25.79 | 1.62 | -4.81 | -4.81 | 330.32 | -- | -- | -- | -- | 7,068,733.00 | -- | -3.27 | -- | -5.35 | 51.77 | 39.95 | -1.52 | -6.17 | -- | 0.7946 | -- | -- | -0.4003 | -0.5816 | 100.10 | -65.75 | -31.71 | -- |
| IOL Chemicals and Pharmaceuticals Ltd | 22.27bn | 1.16bn | 20.95bn | 2.89k | 18.07 | -- | 10.77 | 0.9405 | 3.95 | 3.95 | 75.87 | -- | -- | -- | -- | 7,704,566.00 | -- | 10.26 | -- | 13.42 | 34.42 | 32.57 | 5.20 | 9.33 | -- | 10.46 | -- | 13.68 | -2.51 | 1.88 | -24.82 | -22.49 | 21.61 | 5.92 |
| Bliss GVS Pharma Ltd | 8.68bn | 1.09bn | 22.63bn | 966.00 | 21.01 | -- | 15.37 | 2.61 | 10.18 | 10.18 | 80.97 | -- | -- | -- | -- | 8,986,598.00 | -- | 6.04 | -- | 7.54 | 52.65 | 46.33 | 13.18 | 9.45 | -- | 8.44 | -- | 8.27 | 5.13 | 3.27 | 11.72 | -2.82 | 5.18 | 0.00 |
| Morepen Laboratories Ltd | 17.87bn | 994.48m | 22.86bn | 1.81k | 22.98 | -- | 15.50 | 1.28 | 1.81 | 1.81 | 32.65 | -- | -- | -- | -- | 9,850,214.00 | -- | 8.14 | -- | 12.81 | 33.71 | 31.83 | 5.61 | 5.91 | -- | 5.59 | -- | -- | 7.17 | 16.26 | 22.73 | 28.58 | 65.86 | -- |
| Unichem Laboratories Ltd | 22.14bn | 2.95bn | 23.21bn | 3.33k | 7.89 | -- | 5.54 | 1.05 | 41.79 | 41.79 | 314.32 | -- | -- | -- | -- | 6,654,374.00 | -- | -0.5598 | -- | -0.6977 | 54.06 | 55.09 | 13.32 | -1.18 | -- | 3.47 | -- | -- | 18.25 | 13.85 | 246.67 | -- | -18.68 | -- |
| Hikal Ltd | 17.46bn | -130.00m | 23.69bn | 2.06k | -- | -- | 16.17 | 1.36 | -1.05 | -1.05 | 141.83 | -- | -- | -- | -- | 8,465,567.00 | -- | 4.78 | -- | 7.00 | 55.47 | 48.00 | -0.7447 | 5.71 | -- | 1.21 | -- | 14.83 | 4.21 | 4.29 | 30.46 | 1.46 | -2.77 | 3.13 |
Data as of Mar 04 2026. Currency figures normalised to Indoco Remedies Ltd's reporting currency: Indian Rupee INR
18.43%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Jan 2026 | 4.43m | 4.80% |
| quant Money Managers Ltd.as of 31 Dec 2025 | 4.20m | 4.55% |
| DSP Asset Managers Pvt. Ltd.as of 31 Jan 2026 | 3.70m | 4.01% |
| Franklin Templeton Asset Management (India) Pvt Ltd.as of 30 Jan 2026 | 2.03m | 2.20% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 1.53m | 1.66% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 598.13k | 0.65% |
| Tata Asset Management Pvt Ltd.as of 31 Jan 2026 | 301.87k | 0.33% |
| India Avenue Investment Management Australia Pty Ltd.as of 31 Jan 2026 | 165.42k | 0.18% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 23.95k | 0.03% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 23.75k | 0.03% |
More ▼
Data from 31 Dec 2025 - 26 Feb 2026Source: FactSet Research Systems Inc.
